The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin

Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism*

Kenneth E. Thummel, Diarmuid O’Shea, Mary F. Paine et al. · Clinical Pharmacology & Therapeutics · 1996 · 619 citations

Pharmacy, Pharmacokinetics, Pharmacology +17

Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4.

Thomas Kronbach, Daniel Mathys, Makoto Umeno et al. · Molecular Pharmacology · 1989 · 535 citations

Medicine, Pharmacology, Biochemical Pharmacology +15

Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes.

Joseph C. Kolars, Phyllissa Schmiedlin‐Ren, John D. Schuetz et al. · Journal of Clinical Investigation · 1992 · 533 citations · Full text

Medicine, Molecular Biology, Pharmacology +14

Cyclosporin A drug interactions. Screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes.

Lydiane Pichard, Isabelle Fabre, Gérard Fabre et al. · Drug Metabolism and Disposition · 1990 · 437 citations

Medicine, Pharmacology, Toxicology +17

Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole

Klaus T. Olkkola, Janne T. Backman, Pertti J. Neuvonen · Clinical Pharmacology & Therapeutics · 1994 · 412 citations

Medicine, Pharmacokinetics, Pharmacology +14